OBJECTIVE: To evaluate the technical effectiveness, technical success and patient safety of MR-guided radiofrequency (RF) ablation of liver malignancies using a wide-bore 1.5-T MR system. METHODS: In 110 patients, 56 primary liver lesions and 157 liver metastases were treated in 157 sessions using percutaneous RF ablation. Mean lesion diameter was 20 mm (range 4-54 mm). All planning, procedural and post-interventional control MR investigations were carried out using a wide-bore 1.5-T MR system. Technical success was assessed by a contrast-enhanced MR liver examination immediately after the intervention. Technique effectiveness was assessed by dynamic hepatic MR study 1 month post ablation; mean follow-up period was 24.2 months (range 5-44). RESULTS: Technical success and technique effectiveness were achieved in 210/213 lesions (98.6 %). In 18/210 lesions (8.6 %), local tumour progression occurred 4-28 months after therapy. Seven of these 18 lesions were treated in a second session achieving complete ablation, 6 other lesions were referred to surgery. Overall RF effectiveness rate was 199/213 (93.4 %); overall therapy success (including surgery) was 205/213 (96.2 %). Two major complications (1.3 %) (bleeding and infected biloma) and 14 (8.9 %) minor complications occurred subsequent to 157 interventions. CONCLUSION: Wide-bore MR-guided RF ablation is a safe and effective treatment option for liver lesions.
OBJECTIVE: To evaluate the technical effectiveness, technical success and patient safety of MR-guided radiofrequency (RF) ablation of liver malignancies using a wide-bore 1.5-T MR system. METHODS: In 110 patients, 56 primary liver lesions and 157 liver metastases were treated in 157 sessions using percutaneous RF ablation. Mean lesion diameter was 20 mm (range 4-54 mm). All planning, procedural and post-interventional control MR investigations were carried out using a wide-bore 1.5-T MR system. Technical success was assessed by a contrast-enhanced MR liver examination immediately after the intervention. Technique effectiveness was assessed by dynamic hepatic MR study 1 month post ablation; mean follow-up period was 24.2 months (range 5-44). RESULTS: Technical success and technique effectiveness were achieved in 210/213 lesions (98.6 %). In 18/210 lesions (8.6 %), local tumour progression occurred 4-28 months after therapy. Seven of these 18 lesions were treated in a second session achieving complete ablation, 6 other lesions were referred to surgery. Overall RF effectiveness rate was 199/213 (93.4 %); overall therapy success (including surgery) was 205/213 (96.2 %). Two major complications (1.3 %) (bleeding and infected biloma) and 14 (8.9 %) minor complications occurred subsequent to 157 interventions. CONCLUSION: Wide-bore MR-guided RF ablation is a safe and effective treatment option for liver lesions.
Authors: John R Leyendecker; Gerald D Dodd; Glenn A Halff; Victor A McCoy; Dacia H Napier; Linda G Hubbard; Kedar N Chintapalli; Shailendra Chopra; W Kenneth Washburn; Robert M Esterl; Francisco G Cigarroa; Ruth E Kohlmeier; Francis E Sharkey Journal: AJR Am J Roentgenol Date: 2002-05 Impact factor: 3.959
Authors: Hansjörg Rempp; Rüdiger Hoffmann; Jörg Roland; Alexandra Buck; Antje Kickhefel; Claus D Claussen; Philippe L Pereira; Fritz Schick; Stephan Clasen Journal: Eur Radiol Date: 2011-11-22 Impact factor: 5.315
Authors: Stephan Clasen; Hansjörg Rempp; Andreas Boss; Diethard Schmidt; Jan Fritz; Christina Schraml; Fritz Schick; Claus D Claussen; Philippe L Pereira Journal: J Vasc Interv Radiol Date: 2011-05-06 Impact factor: 3.464
Authors: Junichi Tokuda; William Plishker; Meysam Torabi; Olutayo I Olubiyi; George Zaki; Servet Tatli; Stuart G Silverman; Raj Shekher; Nobuhiko Hata Journal: Acad Radiol Date: 2015-03-14 Impact factor: 3.173
Authors: Susann-Cathrin Olthof; Daniel Wessling; Moritz T Winkelmann; Hansjörg Rempp; Konstantin Nikolaou; Rüdiger Hoffmann; Stephan Clasen Journal: Insights Imaging Date: 2022-03-21
Authors: Moritz T Winkelmann; Rami Archid; Georg Gohla; Gerald Hefferman; Jens Kübler; Jakob Weiss; Stephan Clasen; Konstantin Nikolaou; Silvio Nadalin; Rüdiger Hoffmann Journal: Cancer Imaging Date: 2020-05-27 Impact factor: 3.909
Authors: Antonia Grimm; Moritz Winkelmann; Jakob Weiß; Georg Gohla; Gunnar Blumenstock; Konstantin Nikolaou; Stephan Clasen; Rüdiger Hoffmann Journal: Eur Radiol Exp Date: 2019-09-23
Authors: Moritz T Winkelmann; Georg Gohla; Jens Kübler; Jakob Weiß; Stephan Clasen; Konstantin Nikolaou; Rüdiger Hoffmann Journal: Cardiovasc Intervent Radiol Date: 2020-07-22 Impact factor: 2.740